Cite
HARVARD Citation
Srivastava, M. et al. (2015). Co-targeting of delta-like ligand 4 (DLL4) and vascular endothelial growth factor a (VEGF) with programmed death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses. Journal for immunotherapy of cancer. 3 (2), p. 1. [Online].